journal article·2022-08-11Open access

Alendronate Prevents Early Periprosthetic Bone Loss in Cementless Total Hip Arthroplasty Better Than Simvastatin

Dragos Apostu, Daniel Oltean-Dan, Alexandru Mester, Andrei Maxim, Adrian Bogdan Tigu, Horea Rares Ciprian Benea, Dan Cosma, Doina Piciu

Applied Sciences· Volume 12· Issue 16

Abstract

Background and Objectives: Cementless total hip arthroplasty leads to an early periprosthetic bone loss, which can impair the osseointegration process and lead to a femoral implant migration during early weight-bearing. An altered osseointegration process can lead to aseptic loosening, which is the most frequent late complication in these surgical procedures. The objective of this study was to compare the effect of alendronate and simvastatin in the prevention of early periprosthetic bone loss found in osteoporotic patients. This can lead to earlier weight-bearing in patients, as well as reduce the rate of aseptic loosening. Materials and Methods: Forty-five patients undergoing cementless total hip arthroplasty were equally distributed into three groups: group I (alendronate), group II (simvastatin), and group III (control). The alendronate group received 5 mg of alendronate postoperatively, daily for 8 weeks, and the simvastatin group received 20 mg daily for 4 weeks postoperatively, followed by 40 mg daily for 4 weeks. We determined bone mineral density (BMD), as well as bone serum markers beta cross-laps (β-CTx) and alkaline phosphatase (ALPL) preoperatively, 4 weeks postoperatively, and 8 weeks postoperatively. All patients were not allowed to fully bear weight for 6 weeks postoperatively. Results: Alendronate statistically significantly increases the BMD at one month postoperatively compared to the control group in Gruen zones 5 and 6 (p = 0.042 and p = 0.039). Overall, the BMD was higher in the alendronate group compared to the control group at one month postoperatively (p = 0.043). Alendronate decreased β-CTx bone serum marker compared to control at one month and two months (p = 0.024 and p = 0.012). Moreover, alendronate showed a higher decrease in β-CTx compared to simvastatin at both timelines (p = 0.028 and p = 0.03, respectively). Conclusions: The study shows that alendronate administration following cementless total hip arthroplasty offers better protection against periprosthetic bone loss compared to simvastatin.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Orthopaedic implants and arthroplasty · Total Knee Arthroplasty Outcomes · Orthopedic Infections and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics, Traumatology and Pediatric Orthopaedics, University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Romania

Department of Oral Health, University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania

Research Center for Advanced Medicine MedFuture, Department of Translational Medicine, University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Romania

Nuclear Medicine Department, University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania

Funding

Romanian Ministry of Education and Research, CNCS-UEFISCDI

References (21)

Show source-provided references
1. Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: Estimates from the 2019 Global Burden of Disease Study10.1186/s13075-021-02705-6 ↗
2. Partial versus early full weight-bearing after uncemented total hip arthroplasty: A meta-analysis10.1186/s13018-017-0527-x ↗
3. Long-term outcomes of total hip arthroplasty in patients younger than 55 years: A systematic review of the contemporary literature10.1503/cjs.013118 ↗
4. Current methods of preventing aseptic loosening and improving osseointegration of titanium implants in cementless total hip arthroplasty: A review10.1177/0300060517732697 ↗
5. Systemic drugs that influence titanium implant osseointegration10.1080/03602532.2016.1277737 ↗
6. Tibolone, alendronate, and simvastatin enhance implant osseointegration in a preclinical in vivo model10.1111/clr.13602 ↗
7. Alendronate inhibits periprosthetic bone loss around uncemented femoral components10.1007/s00774-006-0743-7 ↗
8. Selective Use of Low Dose Tranexamic Acid in Orthopedic Surgery
9. Biochemical markers of bone remodeling—Review
10. Partial weightbearing is not necessary after cementless total hip arthroplasty: A two-year prospective randomized study on 100 patients10.1007/s00264-010-1089-2 ↗
11. Implant migration after early weightbearing in cementless hip replacement10.1097/01.blo.0000160380.15429.fb ↗
12. Immediate weight bearing after cementless total hip arthroplasty10.3928/01477447-20080301-40 ↗
13. Reiner, T., Sonntag, R., Kretzer, J.P., Clarius, M., Jakubowitz, E., Weiss, S., Ewerbeck, V., Merle, C., Moradi, B., and Kinkel, S. (2020). The Migration Pattern of a Cementless Hydroxyapatite-Coated Titanium Stem under Immediate Full Weight-Bearing-A Randomized Controlled Trial Using Model-Based RSA. J. Clin. Med., 9.10.3390/jcm9072077 ↗
14. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study10.1111/os.12513 ↗
15. Periprosthetic bone loss after insertion of an uncemented, customized femoral stem and an uncemented anatomical stem. A randomized DEXA study with a 5-year follow-up10.3109/17453674.2011.588860 ↗
16. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty—A 5-year follow-up of 16 patients10.1177/145749691009900108 ↗
17. Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty10.1016/j.arth.2017.02.036 ↗
18. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty10.2106/JBJS.I.01714 ↗
19. The effect of simvastatin on periprosthetic bone mineral density in the hypercholesterolaemic patients after total hip arthroplasty10.1007/s00264-017-3551-x ↗
20. Effects of simvastatin on osseointegration in a canine total hip arthroplasty model: An experimental study10.1016/j.arth.2010.10.008 ↗
21. A 2003 update of bone physiology and Wolff’s Law for clinicians